Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the first line combination hormonal therapy
of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is
more effective than another approved drug, letrozole (Femara®), in delaying the growth of
breast cancer in postmenopausal patients with locally advanced or metastatic breast cancer,
and whether the side effects of the combination are different from the side effects of
letrozole.